安德克萨尼阿尔法与四因子前列红素复合物缩在DOACs抗凝固逆转:一个更新的系统性审查和元分析
Daniele Orso1,2, Federico Fonda3, Alessandro Brussa3
1Azienda Sanitaria Universitaria Friuli Centrale, Department of Emergency "Santa Maria Della Misericordia", University Hospital of Udine, Piazzale Santa Maria Della Misericordia, N.15, 33100, Udine, UD, Italy. sd7782.do@gmail.com.
Critical care (London, England)
|July 5, 2024
概括
安德克萨内特阿尔法没有证明与四因子前列红素复合缩物 (4F-PCC) 相比,在逆转直接口服抗凝剂 (DOAC) 方面有显著的死亡益处. 有控制的研究表明,安德克萨内特α可能会增加血栓栓塞事件的风险.
科学领域:
- 药理学 药理学是指药理学的学科.
- 临床医学 临床医学
- 基于证据的医学基于证据的医学.
背景情况:
- 对于安德克萨内特α与四因子前素复合缩物 (4F-PCC) 在逆转直接口服抗凝剂 (DOACs) 中的有效性比较数据有限.
- 本系统性审查解决了与这些逆转药物相关的死亡率和血栓栓塞事件的证据缺口.
研究的目的:
- 为了比较安德克萨内特α和4F-PCC在降低DOACs患者所有原因的短期死亡率方面的有效性.
- 评估与4F-PCC相比,与安德克桑尼特α相关的血栓栓塞事件的发生率.
主要方法:
- 对22项研究进行了系统审查和元分析.
- 用风险比率 (RR) 与置信区间 (CI) 和异质度 (I2) 来分析死亡率和血栓栓塞事件的比较有效性.
主要成果:
- 与4F-PCC相比,安德克萨内特α在各种研究类型 (RR范围:0.71-0.84) 中没有显示出在减少所有原因的短期死亡率方面具有统计学意义的优势.
- 对受控研究的分析表明,使用安德克萨内特α的血栓栓塞事件的风险较高 (RR: 1.71-1.74).
- 回顾性研究显示,这两种药物之间的血栓栓塞事件没有显著差异 (RR范围:1.18-1.21).
结论:
- 在DOAC逆转方面,安德克萨内特α没有比4F-PCC提供统计学上显著的死亡益处.
- 与4F-PCC相比,在受控研究中使用安德克萨内特α与血栓栓塞事件的风险增加有关.
相关概念视频
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.2K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
672
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
672
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
514
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
514
Coagulation
6.1K
The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.1K
Time Course of Drug Effect
2.0K
The progression of a drug's impact can be analyzed by examining both the concentration-time course and the effect-time course. The concentration-time course is determined by the drug's half-life and is influenced by factors such as its pharmacokinetics, including absorption, distribution, metabolism, and elimination. The effect of the drug is often related to its concentration in the plasma and is calculated using the maximum drug effect and the plasma concentration that generates 50...
2.0K
EDTA: Auxiliary Complexing Reagents
575
EDTA titrations are usually carried out in highly basic conditions, where the fully deprotonated form of EDTA, Y4−, actively complexes with the free metal ions in the solution. Several metal ions precipitate as hydrous oxide (hydroxides, oxides, or oxyhydroxides) under these conditions, lowering the concentration of free metal ions in the solution. For this reason, auxiliary complexing agents or ligands such as ammonia, tartrate, citrate, or triethanolamine are used in EDTA titrations to...
575


